Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
It can occur at any age and the earlier the onset, the more serious is the long-term damage, dysfunction and failure of various organs due to the chronic hyperglycemia with diabetes mellitus patients having <10 year in life span compared to non-DM patients.
Type 1 DM patients have complete insulin deficiency due to beta-cell destruction. It may be immune-mediated or idiopathic. More commonly occurs in children 7-15 year of age, but may occur at any age.
Type 2 DM patients have insulin resistance and relative insulin deficiency.
Neonatal DM is hyperglycemia that occurs in the first 6 months of life.
The glucagon-like peptide 1 (GLP-1) agonist liraglutide can bring sugar levels under control in children with type 2 diabetes (T2D) when added to metformin with or without basal insulin, although such benefit is gained at the expense of an increased frequency of gastrointestinal adverse events (AEs), according to the results of the phase III Ellipse Trial.
A 26-week regimen of liraglutide effectively improved glycaemic control in adolescents with type 2 diabetes (T2D) who had inadequate response to metformin, according to the results of the phase III Ellipse* trial presented as a poster at the recent Pediatric Academic Societies meeting (PAS 2019).
The use of a hybrid closed-loop insulin pump, which has shown promise in improving glycaemic outcomes in adolescents and adults with type 1 diabetes, may also be beneficial in children, according to a study presented at ENDO 2018.
Intranasal delivery of dry powder glucagon in paediatric type 1 diabetes (T1D) patients with moderate to severe hypoglycaemia appears to induce recovery over half an hour, with the rise in blood glucose occurring within 15 minutes, according to a study presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017).
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Autoantigen specific therapy with alum-GAD, an investigational “vaccine” against type 1 diabetes (T1D), did not delay or prevent development of the disease in children aged 4–18 years compared with placebo injections in a small study presented at the ADA 2017 Scientific Sessions in San Diego, California, US.
Caesarean section-born babies for whom antibiotic prescriptions were redeemed during the first 2 years of life were at greater risk of childhood-onset type 1 diabetes (T1D), specifically those treated with extended-spectrum penicillins and macrolides, a Danish cohort study found.
The exposure-response relationship with single oral dose dapagliflozin is similar between adult and paediatric patients with type 2 diabetes mellitus (T2DM), according to an analysis of data from three clinical studies.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS JPOG - Malaysia digital copy today!
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.